Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Sofosbuvir / Velpatasvir (Epclusa & authorized generic by Year
Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) — Rest of World sales ($M) ($M)
Gilead Sciences Sofosbuvir / Velpatasvir (Epclusa & authorized generic: $344M in FY2025, down 8.0% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 344 | -8.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 374 | +5.4% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 355 | +7.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 331 | 0.0% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 331 | -16.8% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 398 | -9.8% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 441 | +16.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 378 | +59.5% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 237 | +1,085.0% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 20 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Sofosbuvir / Velpatasvir (Epclusa & authorized generic ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-epclusa-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.